Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Evaluation the Effect of Ticagrelor and Clopidogrel in Stable Coronary Syndrome A Randomized Clinical Trial

ID
Name
IR.SUMS.MED.REC.1401.351
Description
Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg twice a day. After six months of close follow-up, patients were asked to give a score to their dyspnea and asked about the major advance cardiovascular events ( MACE)
Trial arms
Trial start
2022-10-01
Estimated PCD
2023-03-01
Trial end
2023-03-01
Status
Completed
Treatment
Clopidogrel
Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
Arms:
clopidogrel
Ticagrelor
Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
Arms:
ticagrelor
Size
476
Primary endpoint
dyspnoea
6 months
Number of patients with major adverse cardiovascular events
6 months
Eligibility criteria
Inclusion Criteria: * Experiencing elective percutaneous coronary intervention (PCI). Exclusion Criteria: * Patients diagnosed with hypersensitivity to either ticagrelor or clopidogrel * Active pathological bleeding * Patients who consumed anticoagulants in the course of their medical therapy
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'comparing two antiplatelet drugs , head to head, randomized', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 476, 'type': 'ACTUAL'}}
Updated at
2023-05-16

1 organization

2 products

1 indication

Organization
Shiraz University of Medical Sciences
Product
Clopidogrel
Indication
Stable Chronic Angina
Product
Ticagrelor